Covid Antibodies Endure Over Six Months in China Trial Subjects

  • Top scientist projected confidence over vaccine effectiveness
  • China to produce 1 billion doses by end of 2021, official says

Photographer: Roy Liu/Bloomberg 

Lock
This article is for subscribers only.

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

The amount of Covid-19 antibodies in trial subjects who received China’s experimental vaccines remained high six months after the first shots, said a top Chinese scientist, projecting confidence that the country will be among the first to produce effective inoculation against the coronavirus.